Role in GUIDE.MRD:
Project Leader: Co-leading the consortium in collaboration with the Coordinator. Actively involved in all governing bodies. Leading industry participation.
WP6 Co-Lead: Driving broad external stakeholders’ engagement to define needs, opportunities and challenges related to ctDNA-based MRD testing in Europe.
Expectation of GUIDE.MRD:
An integrated precision oncology approach that can guide the selection of personalized therapy is paramount to achieve improved outcomes for patients.
Bristol Myers Squibb is committed to collaborate with a broad ecosystem of public and private partners under the IHI umbrella to advance the demonstration of the utility in clinical practice of ctDNA tests to measure MRD for solid tumors.
